Two key executives of Novartis AG subsidiary Alcon with responsibility for Asia were fired this week, AsianScientist reported, after confirming the action by the parent company.
Novartis has the first next-gen psoriasis med on the market in Cosentyx, and it's been spending money to take that first-to-market advantage as far as it can. But the Swiss drugmaker wants the treatment to be first in other indications, too. On that front, it got a boost on Wednesday with some new results in ankylosing spondylitis.
These days, companies are increasingly looking to put both branded and generic meds under one roof. And Peter Goldschmidt, the U.S. president of Novartis' Sandoz unit, doesn't know why they didn't do it sooner.
Novartis CEO Joe Jimenez and Chairman Joerg Reinhardt sang the same tune on drug prices in separate interviews over the weekend, backing performance-based drug deals while pointing the finger at other healthcare expenses for driving up overall spending.
Last month, a U.S. appeals court blocked Novartis' biosimilar version of Amgen's blockbuster Neupogen while the companies worked out a patent dispute. Unsurprisingly, though, Novartis wants that ban lifted, and now it's asking the court to do just that.
Novartis won't be pulling the trigger on a $600 million buyout deal for Israel's Gamida Cell after all. Elbit Imaging, the majority owner of a minority stakeholder in the stem cell player, says that the pharma giant has decided not to pursue its option on the company, but has signaled its willingness to push ahead with their collaboration.
Roche has been at the top of the heap in oncology sales for years--and it's no wonder, what with its top-selling triumvirate, Herceptin, Rituxan and Avastin. The Swiss drugmaker racked up more than $25 billion in cancer last year, and its closest challenger, Novartis, managed less than half of that.
The U.K.'s cost-effectiveness gatekeeper, the National Institute for Health and Care Excellence (NICE), has bestowed its favor on a crop of new drugs, granting nods to contenders from Roche, Novartis and Bayer.
Biologic drugs for diseases like diabetes and rheumatoid arthritis remain injectable for now, but Rani Therapeutics' novel oral biologic delivery system just earned a partnership with pharma bigwig Novartis, suggesting that the San Jose startup is on the way to cracking the code.
Novartis unveiled "life hacks" for multiple sclerosis patients, as part of a campaign commemorating World MS Day.